source
- Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beatInvestors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.Fierce Biotech · 6h ago↗ source
- Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOsAttovia Therapeutics, Braveheart Bio and Vogenx have set target ranges for their IPOs, positioning the trio to collectively net more than $500 million from public investors.Fierce Biotech · 7h ago↗ source
- Labcorp posts higher Q2 earnings on strength of diagnostics, lab services; adjusts full-year guidanceLabcorp continues to power along as it posts strong quarterly earnings led by growth in its diagnostics and lab services and triggering the medtech to raise its full-year guidance.